Records containing: Urothelial Carcinoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-04-01Retrospective, Multicenter, Observational Study to Evaluate Current Treatment Patterns and Outcomes in Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With First-line Avelumab Maintenance
-
CLINICAL_TRIALS study record update · 2025-03-26Adjuvant Sacituzumab Govitecan Plus Nivolumab in Patients with Muscle-Invasive Urothelial Carcinoma At High-Risk for Recurrence
-
CLINICAL_TRIALS study record update · 2025-03-21Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
-
CLINICAL_TRIALS study record update · 2025-03-21A Randomized Phase II Trial to Evaluate 9MW2821 in Combination With Toripalimab Compared With 9MW2821 Monotherapy for the 1st Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
-
CLINICAL_TRIALS study record update · 2025-03-18Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-03-14Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
-
CLINICAL_TRIALS study record update · 2025-03-12Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies
-
CLINICAL_TRIALS study record update · 2025-03-10An Open-Label, Randomized, Phase 2, Umbrella Study to Investigate the Biological Rational of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy
-
CLINICAL_TRIALS study record update · 2025-03-06ICRA (Improve Checkpoint-blockade Response in Advanced Urothelial Cancer), an Adaptive Clinical Study to Determine Efficacy of Combining Weekly Paclitaxel With Tremelimumab +/- Durvalumab (MEDI4736)
-
CLINICAL_TRIALS study record update · 2025-03-05A Phase 1b Trial in Stage II-III Urothelial Cancer to Explore Pre-operative Immunotherapy
-
CLINICAL_TRIALS study record update · 2025-03-05Phase 1B Study to Assess Safety and Efficacy of Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)
-
CLINICAL_TRIALS study record update · 2025-02-28uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
-
CLINICAL_TRIALS study record update · 2025-02-28ClinicalTrials.gov study NCT05494411
-
CLINICAL_TRIALS study record update · 2025-02-25A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial Carcinoma
-
CLINICAL_TRIALS study record update · 2025-02-21QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy
-
CLINICAL_TRIALS study record update · 2025-02-17A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors
-
CLINICAL_TRIALS study record update · 2025-02-13A Multicenter, Single-blind, Observational Clinical Trial of URISAFE
-
CLINICAL_TRIALS study record update · 2025-02-12A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 as a Single Agent and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-02-03A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
-
CLINICAL_TRIALS study record update · 2025-01-27A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer
-
CLINICAL_TRIALS study record update · 2025-01-23A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-01-16ABLE: Phase II, Single Arm, Two-stage Study of Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer
-
CLINICAL_TRIALS study record update · 2025-01-10Defining the Genomic and Histologic Landscape of Primary and Metastatic Tumors With Divergent Kinetics in Patients With Renal Cell Carcinoma (RCC) and Urothelial Carcinoma (UC) Treated With Immune Checkpoint Blockade (ICB)
-
CLINICAL_TRIALS study record update · 2025-01-07A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer
-
CLINICAL_TRIALS study record update · 2024-12-18Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)